FDA Commissioner Scott Gottlieb has left agency to rejoin the American Enterprise Institute—a conservative think tank—where he will work part-time on drug pricing issues.

It’s a familiar role for Gottlieb, who was a resident fellow at AEI for more than a decade prior to his appointment as FDA’s chief in May 2017.

Although the FDA has no direct role in drug pricing, Gottlieb sought during his two-year tenure at the agency to address the issue by indirect means, such as by speeding up reviews of generics to spur competition.

Gottlieb also pushed the agency to take action against brand name drug manufacturers that exploited REMS safety controls to delay generic market entry, among other initiatives.